This HTML5 document contains 73 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/bindingdb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/drugbank/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n24http://www.drugs.com/cdi/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/sukl/drug/
n26http://linked.opendata.cz/resource/atc/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01087/identifier/wikipedia/

Statements

Subject Item
n2:DB01087
rdf:type
n5:Drug
n5:description
An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
n5:dosage
n16:271B6435-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM: Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol. 1985 Jun;19(6):745-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/4027117 # ALVING AS, ARNOLD J, HOCKWALD RS, CLAYMAN CB, DERN RJ, BEUTLER E, FLANAGAN CL: Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955 Aug;46(2):301-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13242948 # Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006 Sep;75(3):402-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16968913 # Cohen RJ, Sachs JR, Wicker DJ, Conrad ME: Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med. 1968 Nov 21;279(21):1127-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/5686480 # Coleman MD, Coleman NA: Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996 Jun;14(6):394-405. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8828017
n5:group
approved
n5:halfLife
3.7-7.4 hours
n5:indication
For the treatment of malaria.
owl:sameAs
n4:DB01087 n12:DB01087
dcterms:title
Primaquine
adms:identifier
n10:PA451103 n11:Primaquine n17:8405 n18:4739 n19:50203193 n20:C07627 n21:4908 n22:DB01087 n25:46508222
n5:mechanismOfAction
Primaquine's mechanism of action is not well understood. It may be acting by generating reactive oxygen species or by interfering with the electron transport in the parasite. Also, although its mechanism of action is unclear, primaquine may bind to and alter the properties of protozoal DNA.
n5:packager
n13:271B6430-363D-11E5-9242-09173F13E4C5 n13:271B6431-363D-11E5-9242-09173F13E4C5 n13:271B642E-363D-11E5-9242-09173F13E4C5 n13:271B642F-363D-11E5-9242-09173F13E4C5 n13:271B642D-363D-11E5-9242-09173F13E4C5
n5:synonym
6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline Neo-quipenyl Primaquinum Primaquin Primaquina Primachin Primachinum 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline
n14:hasAHFSCode
n15:08-30-08
n5:foodInteraction
Take with food to decrease dyspepsia.
foaf:page
n24:primaquine.html
n5:IUPAC-Name
n6:271B643A-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B6440-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B643F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B643C-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B643D-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B643E-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B6438-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B6439-363D-11E5-9242-09173F13E4C5 n6:271B6436-363D-11E5-9242-09173F13E4C5 n6:271B6452-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B6437-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n26:P01BA03
n5:H-Bond-Acceptor-Count
n6:271B6446-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B6447-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B6441-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B6442-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B6444-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B6443-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B6445-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Plasmodium
n5:casRegistryNumber
90-34-6
n5:category
n5:containedIn
n7:271B6434-363D-11E5-9242-09173F13E4C5 n7:271B6432-363D-11E5-9242-09173F13E4C5 n7:271B6433-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B644C-363D-11E5-9242-09173F13E4C5
n5:Boiling-Point
n6:271B6451-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B644E-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B644F-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B6450-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B644B-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B644A-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B644D-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B643B-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B6448-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B6449-363D-11E5-9242-09173F13E4C5